The references to MSB are not comparing the respective science merely referencing market development of stem cell application in the treatment of GRHD, for which their is potential application hopefully of CYP's manufacturing process. It also is highlighting the focus of the Japanese on developing stem cell solutions and bringing to market products as soon as practicable. This in turn should drive demand for cell manufacturing but importantly in the short term serves well to highlight the broader development of stem cell therapies to treat serious medical treatments (and the Japanese Govt's financial support for same). Nothing negative there from where i sit.
The references to MSB are not comparing the respective science...
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $52.99M | |||
| Open | High | Low | Value | Volume |
| 27.0¢ | 29.5¢ | 27.0¢ | $3.372K | 11.64K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 39000 | 28.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 1608 | 1 |
View Market Depth
| Last trade - 11.40am 01/07/2024 (20 minute delay) ? |
| CYP (ASX) Chart |